Mozobil 20 mg/ml solution for injection
Sponsors
Vertex Pharmaceuticals Inc., Rocket Pharmaceuticals Inc., Fondazione Telethon Ets, San Raffaele Hospital
Conditions
Autosomal recessive osteopetrosis caused by mutations in the TCIRG1 geneInherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cellsPyruvate Kinase DeficiencySickle cell anaemia
Phase 1
Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Adult and Pediatric Subjects with PKD
CompletedCTIS2024-511520-13-00
Start: 2019-11-04End: 2025-06-09Target: 3Updated: 2025-05-05
A phase I/II open label study to assess safety, feasibility and efficacy of ex vivo expanded, autologous haematopoietic stem and progenitor cell populations that contain CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA in children with autosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene.
Not yet recruitingCTIS2024-518972-30-00
Target: 8Updated: 2025-08-06